Cellectis SA
CLLS
查看詳細走勢圖
4.690USD
+0.320+7.32%
收盤 12/22, 16:00（美東）報價延遲15分鐘
339.21M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+7.32%
5天
-2.09%
1月
0.00%
6月
+219.05%
今年開始到現在
+160.56%
1年
+185.98%
查看詳細走勢圖
TradingKey Cellectis SA股票評分
單位: USD 更新時間: 2025-12-22操作建議
Cellectis SA當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名159/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價7.17。中期看，股價處於上升通道。近一個月，市場表現較差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Cellectis SA評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
7
分析師
買入
評級
7.167
目標均價
+55.12%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Cellectis SA亮點
亮點風險
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
業績高增長
公司營業收入穩步增長，連續3年增長91.32%
業績增長期
公司處於發展階段，最新年度總收入49.22M美元
估值低估
公司最新PE估值-14.26，處於3年歷史低位
貝利・吉福德持倉
明星投資者貝利・吉福德持倉，最新持倉0.00股
Cellectis SA新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Cellectis SA簡介
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
公司代碼CLLS
公司Cellectis SA
CEOSourdive (David J.D)
網址https://www.cellectis.com/
常見問題
Cellectis SA(CLLS)的當前股價是多少？
Cellectis SA(CLLS)的當前股價是 4.690。
Cellectis SA 的股票代碼是什麼？
Cellectis SA的股票代碼是CLLS。
Cellectis SA股票的52週最高點是多少？
Cellectis SA股票的52週最高點是5.480。
Cellectis SA股票的52週最低點是多少？
Cellectis SA股票的52週最低點是1.100。
Cellectis SA的市值是多少？
Cellectis SA的市值是339.21M。
Cellectis SA的淨利潤是多少？
Cellectis SA的淨利潤為-36.76M。
現在Cellectis SA(CLLS)的股票是買入、持有還是賣出？
根據分析師評級，Cellectis SA(CLLS)的總體評級為買入，目標價格為7.167。
Cellectis SA(CLLS)股票的每股收益（EPS TTM）是多少
Cellectis SA(CLLS)股票的每股收益（EPS TTM）是-0.329。
相關品種
+0.44%
+0.43%
+0.45%
+0.21%
+0.60%
+3.60%
+1.22%
+0.04%
-0.10%
+0.10%
-0.31%
+0.90%
+0.82%
-0.25%
-0.02%
+0.71%
+1.48%
0.00%
+1.25%
+1.87%
